A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment

Lymphoma patients often receive high glucocorticoid doses as part of standard therapy. Observational studies have shown a substantial risk of glucocorticoid-induced osteoporosis (GIO) with associated fractures. The aim of the SIESTA trial was to determine if oral alendronate (ALN) is a safe and effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Paw, Jakobsen, Lasse Hjort, Bøgsted, Martin, Baech, Joachim, Lykkeboe, Simon, Severinsen, Marianne Tang, Vestergaard, Peter, El-Galaly, Tarec Christoffer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043936/
https://www.ncbi.nlm.nih.gov/pubmed/35045567
http://dx.doi.org/10.1182/bloodadvances.2021006330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043936/
https://www.ncbi.nlm.nih.gov/pubmed/35045567
http://dx.doi.org/10.1182/bloodadvances.2021006330

Ejemplares similares